Joshua Cohen is Co-Chief Executive Officer and Director of Amylyx Pharmaceuticals, Inc. (AMLX). The company reported total compensation of $2,719,807 for fiscal year 2025.
| Salary | $686,200 |
|---|---|
| Bonus | $0 |
| Stock awards | $650,226 |
| Option awards | $817,783 |
| Non-equity incentive plan | $548,098 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $17,500 |
| Total | $2,719,807 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Amylyx Pharmaceuticals, Inc. filed April 23, 2026, accession 0001193125-26-171800.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Justin Klee | Co-Chief Executive Officer and Director | $2,719,807 |
| Joshua Cohen this page | Co-Chief Executive Officer and Director | $2,719,807 |
| Camille Bedrosian | Chief Medical Officer | $1,567,674 |
| James Frates | Chief Financial Officer | $1,375,327 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Amylyx Pharmaceuticals, Inc. compensation brief.
Joshua Cohen's compensation sits inside Amylyx Pharmaceuticals, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.